Cargando…

Is the Triggering of PD-L1 Dimerization a Potential Mechanism for Food-Derived Small Molecules in Cancer Immunotherapy? A Study by Molecular Dynamics

Using small molecules to inhibit the PD-1/PD-L1 pathway is an important approach in cancer immunotherapy. Natural compounds such as capsaicin, zucapsaicin, 6-gingerol and curcumin have been proposed to have anticancer immunologic functions by downregulating the PD-L1 expression. PD-L1 dimerization p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xiaoyan, Wang, Na, Liang, Jianhuai, Wang, Bingfeng, Jin, Yulong, Liu, Boping, Yang, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864258/ https://www.ncbi.nlm.nih.gov/pubmed/36674929 http://dx.doi.org/10.3390/ijms24021413

Ejemplares similares

Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation
por: Liang, Jianhuai, et al.
Publicado: (2023)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

Molecular Mechanism of Food-Derived Polyphenols on PD-L1 Dimerization: A Molecular Dynamics Simulation Study
por: Guo, Yan, et al.
Publicado: (2021)

Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship
por: Shi, Danfeng, et al.
Publicado: (2019)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment
por: Cheng, Binbin, et al.
Publicado: (2023)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1
por: Ahmed, Marawan, et al.
Publicado: (2022)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
por: Ganesan, Aravindhan, et al.
Publicado: (2019)

The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
por: Zhong, Yanwen, et al.
Publicado: (2019)

Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
por: Yang, Yuanyuan, et al.
Publicado: (2022)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
por: Sun, Chengliang, et al.
Publicado: (2022)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

The role of exosomal PD-L1 in tumor immunotherapy
por: Wang, Jing, et al.
Publicado: (2021)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
por: Koblish, Holly K., et al.
Publicado: (2022)

CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
por: Musielak, Bogdan, et al.
Publicado: (2019)

Coumarin Dimer Is an Effective Photomechanochemical AND Gate for Small-Molecule Release
por: He, Xiaojun, et al.
Publicado: (2023)

The dynamic dimer structure of the chaperone Trigger Factor
por: Morgado, Leonor, et al.
Publicado: (2017)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
por: Zhang, Hao, et al.
Publicado: (2023)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy
por: Cai, Shuxian, et al.
Publicado: (2021)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017)

Small-Molecule Targets in Tumor Immunotherapy
por: Zhu, Hui-Fang, et al.
Publicado: (2018)

Small-Molecule PROTACs for Cancer Immunotherapy
por: Liu, Zefan, et al.
Publicado: (2022)

Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules
por: Kim, Jee Hye, et al.
Publicado: (2016)

A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
por: Kong, Xianbin, et al.
Publicado: (2021)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_19umth6ffe4epp96o0g3tvg7e5